Will stem cell-based treatments make a difference to the developing world?

September 11, 2006

A new study in the open access journal PLoS Medicine suggests that developing countries could benefit enormously from the new field of regenerative medicine, in which treatments are being developed from stem cells.

Developing countries are increasingly struggling to manage epidemic rates of chronic diseases, like diabetes, stroke, and heart disease, and it is expected that stem cell research could lead to better treatments for such chronic conditions.

In the study, by Abdallah Daar (McLaughlin Centre for Molecular Medicine, University of Toronto) and colleagues, an international panel of 44 experts ranked the ten most promising applications of regenerative medicine for improving health in developing countries. The experts included researchers in disciplines contributing to regenerative medicine and clinicians working in fields that will be at the forefront of applying regenerative medicine therapies.

The top-ranked application was novel methods of insulin replacement and pancreatic islet cell regeneration for diabetes. The panelists ranked this number one because of the high prevalence of diabetes in developing countries and the major health, social, and economic burden that results. Panelists emphasized that controlling diabetes would in turn reduce the incidence of diabetes complications such as blindness, heart disease, chronic kidney disease, and diabetic ulcers.

The panelists noted that repeated insulin treatments are costly and inaccessible to many patients in developing countries. They felt that regenerative medicine therapies, such as bone marrow stem cell transplantation or microencapsulated islet cells using new biomaterials, could provide a permanent solution to treating diabetes and reduce the financial burden caused by the purchase of insulin.

The second-ranked application was regenerating failed heart muscle using the patient's own cells, injected directly or introduced via patches, for treating heart muscle damage due to a heart attack or a cardiomyopathy (a condition causing weakness of the heart muscle). Panelists noted that such therapy shows promising early results, and is being tested in clinical trials in a number of countries.

Other highly ranked applications were immune system enhancement by engineered immune cells, new vaccination strategies for treating infectious diseases, new stem cell-based technologies for replacing skin loss due to burns, wounds, and diabetic ulcers, and new blood substitutes.

The study results, say the authors, "may be used as a guide for the policy formulation of international and bilateral aid agencies, and by developing countries to help target policy aimed at initiating or developing further their existing capacity in regenerative medicine."
-end-
All works published in PLoS Medicine are open access. Everything is immediately available without cost to anyone, anywhere--to read, download, redistribute, include in databases, and otherwise use--subject only to the condition that the original authorship is properly attributed. Copyright is retained by the authors. The Public Library of Science uses the Creative Commons Attribution License.

Citation: Greenwood HL, Singer PA, Downey GP, Martin DK, Thorsteinsdóttir H, et al. (2006) Regenerative medicine and the developing world. PLoS Med 3(9): e381

PLEASE ADD THE LINK TO THE PUBLISHED ARTICLE IN ONLINE VERSIONS OF YOUR REPORT: http://dx.doi.org/10.1371/journal.pmed.0030381

PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-03-09-daar.pdf

Related image for press use: http://www.plos.org/press/plme-03-09-daar.jpg

Caption: Countries Represented on the Expert Panel

CONTACT:
Abdallah Daar
University of Toronto
Joint Centre for Bioethics
88 College Street
Toronto, Ontario M5G 1L4 Canada
+1-647-388-9313
+1-416-352-1606 (fax)
a.daar@utoronto.ca

Researchers Heather L. Greenwood, Peter A. Singer, Gregory P. Downey, Douglas K. Martin, Halla Thorsteinsdóttir and Abdallah S. Daar are available for advance interviews Sept. 7-11. To schedule an interview, call Terry Collins at +1-416-538-8712 or +1-416-878-8712 or e-mail terrycollins@rogers.com.

About PLoS Medicine

PLoS Medicine is an open access, freely available international medical journal. It publishes original research that enhances our understanding of human health and disease, together with commentary and analysis of important global health issues. For more information, visit http://www.plosmedicine.org

About the Public Library of Science

The Public Library of Science (PLoS) is a non-profit organization of scientists and physicians committed to making the world's scientific and medical literature a freely available public resource. For more information, visit http://www.plos.org

PLOS

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.